Summary:
In patients with heart failure with preserved ejection fraction, obesity (BMI ≥30), and type 2 diabetes, once-weekly semaglutide (2.4 mg) injection for 52 weeks significantly improved heart failure-related symptoms and physical limitations (mean difference: 7.3 points, P<0.001) and resulted in greater weight loss (-6.4%, P<0.001) compared to placebo injections administered once weekly, though it was associated with fewer serious adverse events reported in the semaglutide group (17.7% vs. 28.8%).
| PICO | Description |
|---|---|
| Population | Patients with heart failure with preserved ejection fraction, obesity (BMI ≥30), and type 2 diabetes. Total participants: 616. |
| Intervention | Once-weekly semaglutide (2.4 mg) injection for 52 weeks. |
| Comparison | Placebo injection administered once weekly for 52 weeks. |
| Outcome | After one year, semaglutide significantly improved heart failure-related symptoms and physical limitations as measured by the Kansas City Cardiomyopathy Questionnaire clinical summary score (mean change: 13.7 vs. 6.4 points; difference: 7.3, 95% CI: 4.1–10.4, P<0.001). Semaglutide also led to greater weight loss (-9.8% vs. -3.4%; difference: -6.4%, 95% CI: -7.6% to -5.2%, P<0.001). Improvements in secondary outcomes (6-minute walk distance, C-reactive protein levels, and a hierarchical composite endpoint) also favored semaglutide. Fewer serious adverse events were reported in the semaglutide group (17.7%) compared to placebo (28.8%). |
Source: Kosiborod, Mikhail N, et al. “Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.” New England Journal of Medicine, 2024 Apr 18;390(15):1394-1407. Read article here.
